PMID- 20608995
OWN - NLM
STAT- MEDLINE
DCOM- 20110810
LR  - 20220408
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 25
IP  - 3
DP  - 2011 Jun
TI  - Effects of pravastatin and rosuvastatin on the generation of adiponectin in the 
      visceral adipose tissue in patients with coronary artery disease.
PG  - 378-87
LID - 10.1111/j.1472-8206.2010.00847.x [doi]
AB  - Pravastatin increases the plasma adiponectin level. We examined whether this is a 
      statins' class effect or specific to pravastatin. Of 50 patients undergoing 
      cardiac surgery for coronary artery disease (CAD, n = 36) and valvular heart 
      disease (VHD, n = 14), 23 with CAD and serum LDL-cholesterol level >100 mg/dL 
      were randomized to pravastatin at 10 mg/day (PRAVA, n = 12) or rosuvastatin at 
      2.5 mg/day (ROSUVA, n = 11) for 2 months, and the other 13 with CAD and 
      LDL-cholesterol </=100 mg/dL were not treated with statin (Non-statin, n = 13). 
      Patients with VHD did not have CAD and were not treated with statin. Blood was 
      sampled at baseline and surgery. Visceral (VIS) and subcutaneous (SC) adipose 
      tissues were harvested during surgery. At baseline, the plasma adiponectin level 
      was low in patients with CAD compared with that of patients with VHD. At surgery, 
      adiponectin level in PRAVA was increased to the level in VHD, whereas those in 
      ROSUVA and Non-statin were unchanged. VIS contents and gene expressions of 
      adiponectin in PRAVA and VHD were similar to each other and were both higher than 
      those in Non-statin and ROSUVA. SC content and gene expression of adiponectin 
      were similar among 4 groups. Protein carbonyl (PC) level, an indicator of 
      oxidative stress, in VIS was lower in PRAVA and VHD than in ROSUVA and 
      Non-statin. There was a negative correlation between the plasma adiponectin and 
      VIS PC levels (r = -0.41, P < 0.05). Thus, pravastatin increases adiponectin 
      generation, whereas rosuvastatin does not.
CI  - (c) 2010 The Authors Fundamental and Clinical Pharmacology (c) 2010 Societe Francaise 
      de Pharmacologie et de Therapeutique.
FAU - Yokoyama, Hiroaki
AU  - Yokoyama H
AD  - Department of Cardiology, Hirosaki University Graduate School of Medicine, 
      Hirosaki, Japan. okumura@cc.hirosaki-u.ac.jp
FAU - Saito, Shin
AU  - Saito S
FAU - Daitoku, Kazuyuki
AU  - Daitoku K
FAU - Fukuda, Ikuo
AU  - Fukuda I
FAU - Higuma, Takumi
AU  - Higuma T
FAU - Hanada, Hiroyuki
AU  - Hanada H
FAU - Osanai, Tomohiro
AU  - Osanai T
FAU - Okumura, Ken
AU  - Okumura K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Adiponectin)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Fluorobenzenes)
RN  - 0 (Interleukin-6)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfonamides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Adiponectin/*biosynthesis/blood/genetics/metabolism
MH  - Aged
MH  - Cholesterol, LDL/blood
MH  - Coronary Artery Disease/blood/*drug therapy/genetics/*metabolism
MH  - Female
MH  - Fluorobenzenes/*pharmacology
MH  - Heart Valve Diseases/genetics/metabolism
MH  - Humans
MH  - Interleukin-6/blood/genetics
MH  - Intra-Abdominal Fat/drug effects/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/drug effects
MH  - Pravastatin/*pharmacology
MH  - Protein Carbonylation/drug effects
MH  - Pyrimidines/*pharmacology
MH  - Rosuvastatin Calcium
MH  - Subcutaneous Fat/metabolism
MH  - Sulfonamides/*pharmacology
MH  - Tumor Necrosis Factor-alpha/blood/genetics
EDAT- 2010/07/09 06:00
MHDA- 2011/08/11 06:00
CRDT- 2010/07/09 06:00
PHST- 2010/07/09 06:00 [entrez]
PHST- 2010/07/09 06:00 [pubmed]
PHST- 2011/08/11 06:00 [medline]
AID - FCP847 [pii]
AID - 10.1111/j.1472-8206.2010.00847.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2011 Jun;25(3):378-87. doi: 
      10.1111/j.1472-8206.2010.00847.x.